Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment
Table 4
Differences in the percentage and absolute number of central memory T cell subpopulations at baseline according to the clinical outcome in dimethyl fumarate- or fingolimod-treated patients.
Lymphocyte subpopulations at baseline
Total cohort ()
DMF ()
Fingolimod ()
MRI activity (no MRI activity, )
Relapses (nonrelapsed, )
MRI activity (no MRI activity, )
Relapses (nonrelapsed, )
MRI activity (no MRI activity, )
Relapses (nonrelapsed, )
value
value
value
value
value
value
CD4+ TCM (%)
0.147
0.154
0.057
0.561
0.609
0.034
Th1CM (%)
0.326
0.049
0.505
0.289
0.637
0.093
Th17CM (%)
0.878
0.06
0.502
0.557
0.477
0.345
Th1Th17CM (%)
0.006
0.002
0.09
0.842
0.062
0.040
CD4+ TCM (cel/μL)
0.515
0.048
0.057
0.980
0.998
0.020
Th1CM (cel/μL)
0.150
0.877
0.088
0.443
0.679
0.059
Th17CM (cel/μL)
0.156
0.746
0.440
0.391
0.235
0.134
Th1Th17CM (cel/μL)
0.168
0.190
0.192
0.540
0.512
0.052
DMF: dimethyl fumarate; CD4+ TCM: central memory CD4 T lymphocytes; Th1CM: Th1 central memory lymphocytes; Th17CM: Th17 central memory lymphocytes; Th1Th17CM: Th1Th17 central memory lymphocytes; MRI: magnetic resonance imaging. values in bold indicate statistically significance.
